We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
+9.04%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$185M
AUM Growth
+$7.74M
Cap. Flow
+$12.1M
Cap. Flow %
6.51%
Top 10 Hldgs %
70.79%
Holding
30
New
10
Increased
8
Reduced
8
Closed
3

Top Buys

Rank Stock Value
1
ENTA icon
Enanta Pharmaceuticals
ENTA
+$9.82M
2
VNDA icon
Vanda Pharmaceuticals
VNDA
+$9.25M
3
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$8.89M
4
NEOS
Neos Therapeutics, Inc
NEOS
+$4.27M
5
CUTR
Cutera, Inc.
CUTR
+$3.82M

Top Sells

Rank Stock Value
1
SCLN
Sciclone Pharmaceuticals Inc
SCLN
+$14.5M
2
ALR
Alere Inc
ALR
+$8.43M
3
SCTL
Societal CDMO, Inc. Common Stock
SCTL
+$7.98M
4
CORV
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
+$4.21M
5
ALIM
Alimera Sciences
ALIM
+$3.42M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CDNA icon
26
CareDx
CDNA
$2.05B
$212K 0.11%
+190,909
New +$203K
FOMX
27
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$13K 0.01%
+2,878
New +$12.8K
EBS icon
28
Emergent Biosolutions
EBS
$394M
– –
-54,505
Closed -$1.58M
VXRT
29
DELISTED
Vaxart
VXRT
– –
-28,584
Closed -$205K
XOMA
30
DELISTED
Xoma
XOMA
– –
-87,960
Closed -$625K
1
2

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q2 2017 Portfolio in Review

As of Q2 2017, Stonepine Capital Management held 30 positions worth $185M, up 4.4% from $177M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Stonepine Capital Management deployed $12.1M of net new capital in Q2 2017, opening 10 new positions and adding to 8 existing holdings. Its largest new stake was CTI BioPharma Corp. (DE) Common Stock: 2,284,381 shares worth $7.56M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 93% a quarter earlier.

On the sell side, the largest reduction was Sciclone Pharmaceuticals Inc, an estimated $14.5M trimmed.

  • Stonepine Capital Management's largest Q2 2017 buy was CTI BioPharma Corp. (DE) Common Stock: 2,284,381 shares worth $7.56M.
  • Stonepine Capital Management added most to Enanta Pharmaceuticals in Q2 2017, an estimated $9.82M increase.
  • Stonepine Capital Management's biggest Q2 2017 reduction was Sciclone Pharmaceuticals Inc, cutting an estimated $14.5M.
  • Stonepine Capital Management fully exited Emergent Biosolutions in Q2 2017, selling an estimated $1.58M.
  • Stonepine Capital Management's ten largest holdings make up 71% of its $185M portfolio in Q2 2017.
  • Stonepine Capital Management opened 10 new positions and closed 3 in Q2 2017.
  • Stonepine Capital Management's portfolio value rose 4.4% quarter-over-quarter to $185M.

Based on Stonepine Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.